Nourianz (Istradefylline) Patent Expiration, LOE Window & CMS Spending
Nourianz (Istradefylline) by Kyowa Kirin: FDA Orange Book LOE 2028-01-28, 0 AB generics, $52.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Kyowa Kirin |
| FDA Application & Pathway | N022075 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-01-28 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $52.7M |
| 2024 Medicare Part D Spend | $50.7M |
| 2024 Medicaid Spend | $1.9M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 20.2% 2-yr change) |